CDNA
- CareDx, Inc
()
Overview
Company Summary
CareDx, Inc (CDNA) is a precision medicine company that specializes in developing diagnostics solutions to improve the results of transplant patients. The company primarily focuses on organ transplant patients, specifically those who have received heart, lung, kidney, liver, or pancreas transplants.
CareDx offers a suite of products and services to address the various stages of the transplant patient care cycle. Their flagship product is AlloSure, a non-invasive genetic sequencing test that measures genetic material from the donor organ in the patient's blood. AlloSure helps clinicians determine if transplanted organs are functioning properly and if any rejection risk exists.
In addition to AlloSure, CareDx provides AlloMap, a blood-based gene expression test that assesses the risk of rejection in heart transplant recipients. This test helps physicians tailor immunosuppressive treatment to each patient individually, reducing the risk of rejection and improving overall patient outcomes.
CareDx also offers a range of diagnostic tools and testing services that aid in post-transplant management. These include AlloSeq, a targeted gene sequencing test that monitors mutations and identifies potential infections or diseases, and Olerup, a line of tools used for human leukocyte antigen (HLA) typing and antibody detection.
Furthermore, CareDx has a comprehensive data management platform called HeartCare. This platform collects and analyzes patient data, enabling clinicians to make data-driven decisions and enhance patient care.
Overall, CareDx is committed to improving the success rates of transplant procedures by providing advanced diagnostic solutions and personalized treatment strategies. Their focus on precision medicine allows them to assist clinicians in achieving better outcomes for transplant patients, ultimately enhancing the quality of life for those who have undergone transplantation.